person
as of 2026-07-01Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST)Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)Call 1-877-CTLILLY(1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)Call 1-877-CTLILLY(1-877-285-4559) or 1-317-615-4559 Mon-Fri 9AM-5PM Eastern time(UTC/GMT-5hours, EST)Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
at a glance
Roles: Study Director
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
Eli Lilly and Company
Roles
Study Director
Trial investigator
no
Trials led
40
Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic Treatment
NCT00191555Phase 4Completed
Study in Adolescents With Schizophrenia or Bipolar Disorder
NCT00982020Phase 4Completed
A Study of Brenipatide in Adult Participants With Schizophrenia
NCT07410507Phase 2Recruiting
Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia
NCT00051298Phase 3Completed
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
NCT01052103Phase 2Completed
Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in Patients With Schizophrenia
NCT00485901Phase 3Completed
Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00088049Phase 4Completed
Zyprexa® Relprevv™ Patient Care Program
NCT01088386—Enrolling By Invitation
Managing Acute Schizophrenia, a Comparison Between Two Atypical Antipsychotics
NCT00485498Phase 4Completed
Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia
NCT00088478Phase 3Completed
A Study Using Rapid Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia
NCT00316238Phase 2Completed
A Physical Dependence Study in Schizophrenia
NCT01452919Phase 3Completed
Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia
NCT00485823Phase 4Completed
A Study of Olanzapine in Patients With Schizophrenia
NCT00970281Phase 3Completed
A Study of LY2140023 in Patients With Schizophrenia
NCT01307800Phase 3Terminated
Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00103571Phase 4Completed
A Study for Patients With Schizophrenia
NCT00520923Phase 2Completed
Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine
NCT00401973Phase 3Completed
Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia
NCT00337662Phase 4Completed
Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder
NCT00190749Phase 4Completed
A Long-Term Study in Schizophrenia
NCT01487083Phase 3Terminated
Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder
NCT00113594Phase 3Completed
A Study of Safety and Tolerability in Subjects With Schizophrenia
NCT01354353Phase 1Completed
Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia
NCT00320489Phase 3Completed
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
STUDY_DIRECTOR